UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor

Journal of clinical oncology, 2004-01, Vol.22 (1), p.175-184

2004

Volltextzugriff (PDF)

Assessing Analgesic Use in Patients with Advanced Cancer: Development of a New Scale—The Analgesic Quantification Algorithm

Pain medicine (Malden, Mass.), 2014-02, Vol.15 (2), p.225-232

2014

Volltextzugriff (PDF)

Reply to Araki et al

European journal of cancer (1990), 2013-06, Vol.49 (9), p.2266-2268

2013

Volltextzugriff (PDF)

New systemic frontline treatment for metastatic colorectal carcinoma

Cancer, 2004-04, Vol.100 (8), p.1558-1577

2004

Volltextzugriff (PDF)

Transmembrane and Soluble Isoforms of Heparin-Binding Epidermal Growth Factor–Like Growth Factor Regulate Distinct Processes in the Pancreas

Gastroenterology (New York, N.Y. 1943), 2009-11, Vol.137 (5), p.1785-1794

2009

Volltextzugriff (PDF)

Lysophosphatidic acid, a disintegrin and metalloprotease-17 and heparin-binding epidermal growth factor- like growth factor in ovarian cancer : The first word, not the last

Clinical cancer research, 2005-07, Vol.11 (13), p.4639-4643

2005

Volltextzugriff (PDF)

A phase 3 open-label, randomized, multicenter study of imprime PGG in combination with cetuximab in patients with KRAS wild type metastatic colorectal cancer

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS3635-TPS3635

2015

Volltextzugriff (PDF)

A phase 3 open-label, randomized, multicenter study of Imprime PGG in combination with cetuximab in patients with KRAS wild type metastatic colorectal cancer

Journal of clinical oncology, 2015-01, Vol.33 (3_suppl), p.TPS787-TPS787

2015

Volltextzugriff (PDF)

Durability and characteristics of objective tumor responses with the innate immune cell modulator Imprime PGG in combination with standard of care frontline treatment for patients (Pts) with metastatic non-squamous NSCLC

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3070-3070

2015

Volltextzugriff (PDF)

The evaluation of denosumab safety in patients with chronic kidney disease: An open-label study

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e20649-e20649

2014

Volltextzugriff (PDF)

A phase (Ph) 1/2 trial of rituximab (RX), imprime PGG (IP), and alemtuzumab (AL) in the early treatment of patients (Pts) with high risk chronic lymphocytic leukemia (CLL)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.7078-7078

2015

Volltextzugriff (PDF)

Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal-related events (SREs) in patients with metastatic bone disease: Subgroup analyses by baseline characteristics

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.9501-9501

2014

Volltextzugriff (PDF)

A randomized, double-blind, multinational trial comparing denosumab with zoledronic acid for treatment of bone disease in adults with newly diagnosed multiple myeloma

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS8628-TPS8628

2014

Volltextzugriff (PDF)

Safety of Imprime PGG, a novel innate immune cell modulator, in adults with stage IV non-small cell lung cancer: an integrated analysis of two randomized phase 2 studies

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3071-3071

2015

Volltextzugriff (PDF)

Phase Ib study of PGG beta glucan in combination with anti-MUC1 antibody (BTH1704) and gemcitabine for the treatment of advanced pancreatic cancer

Journal of clinical oncology, 2015-01, Vol.33 (3_suppl), p.TPS493-TPS493

2015

Volltextzugriff (PDF)

Denosumab For The Treatment Of Hypercalcemia Of Malignancy Refractory To IV Bisphosphonates In Patients With Hematologic Malignancies

Blood, 2013-11, Vol.122 (21), p.2536-2536

2013

Volltextzugriff (PDF)

Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase III clinical trial

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.TPS670-TPS670

2012

Volltextzugriff (PDF)

Incidence of osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases from solid tumors or multiple myeloma: Results from three phase III trials

Journal of clinical oncology, 2013, Vol.31 (15_suppl), p.9640-9640

2013

Volltextzugriff (PDF)

Health state preferences associated with subcutaneous injections and intravenous infusions for treatment of bone metastases

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e16528-e16528

2012

Volltextzugriff (PDF)

A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer

Journal for immunotherapy of cancer, 2014-11, Vol.2 (Suppl 3), p.P71-P71

2014

Volltextzugriff (PDF)

Phase III trials in oncology: setting standards of care?

Nature clinical practice. Oncology, 2005-09, Vol.2 (9), p.426-427

2005

Volltextzugriff (PDF)

Transmembrane and soluble isoforms of heparin-binding EGF-like growth factor regulate distinct processes in the pancreas

Gastroenterology (New York, N.Y. 1943), 2009-08, Vol.137 (5), p.1785-1794

2009

Volltextzugriff (PDF)

Dual function of Langerhans cells in skin TSLP-promoted TFH differentiation in mouse atopic dermatitis

Journal of allergy and clinical immunology, 2021-05, Vol.147 (5), p.1778-1794

2021

Volltextzugriff (PDF)

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

Journal of clinical oncology, 2010-12, Vol.28 (35), p.5132-5139

2010

Volltextzugriff (PDF)

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

European journal of cancer (1990), 2012-11, Vol.48 (16), p.3082-3092

2012

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(35)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

Journal Of Clinical Oncology
(19)
European Journal Of Cancer
(3)
Clinical Cancer Research
(2)
Gastroenterology
(2)
Journal Of Allergy And Clinical Immunology
(2)
Anti-Cancer Drugs
(1)
Biochemistry
(1)
Blood
(1)
Cancer
(1)
J Clin Oncol
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor

Assessing Analgesic Use in Patients with Advanced Cancer: Development of a New Scale—The Analgesic Quantification Algorithm

Reply to Araki et al

New systemic frontline treatment for metastatic colorectal carcinoma

Transmembrane and Soluble Isoforms of Heparin-Binding Epidermal Growth Factor–Like Growth Factor Regulate Distinct Processes in the Pancreas

Lysophosphatidic acid, a disintegrin and metalloprotease-17 and heparin-binding epidermal growth factor- like growth factor in ovarian cancer : The first word, not the last

A phase 3 open-label, randomized, multicenter study of imprime PGG in combination with cetuximab in patients with KRAS wild type metastatic colorectal cancer

A phase 3 open-label, randomized, multicenter study of Imprime PGG in combination with cetuximab in patients with KRAS wild type metastatic colorectal cancer

Durability and characteristics of objective tumor responses with the innate immune cell modulator Imprime PGG in combination with standard of care frontline treatment for patients (Pts) with metastatic non-squamous NSCLC

The evaluation of denosumab safety in patients with chronic kidney disease: An open-label study

A phase (Ph) 1/2 trial of rituximab (RX), imprime PGG (IP), and alemtuzumab (AL) in the early treatment of patients (Pts) with high risk chronic lymphocytic leukemia (CLL)

Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal-related events (SREs) in patients with metastatic bone disease: Subgroup analyses by baseline characteristics

A randomized, double-blind, multinational trial comparing denosumab with zoledronic acid for treatment of bone disease in adults with newly diagnosed multiple myeloma

Safety of Imprime PGG, a novel innate immune cell modulator, in adults with stage IV non-small cell lung cancer: an integrated analysis of two randomized phase 2 studies

Phase Ib study of PGG beta glucan in combination with anti-MUC1 antibody (BTH1704) and gemcitabine for the treatment of advanced pancreatic cancer

Denosumab For The Treatment Of Hypercalcemia Of Malignancy Refractory To IV Bisphosphonates In Patients With Hematologic Malignancies

Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase III clinical trial

Incidence of osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases from solid tumors or multiple myeloma: Results from three phase III trials

Health state preferences associated with subcutaneous injections and intravenous infusions for treatment of bone metastases

A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer

Phase III trials in oncology: setting standards of care?

Transmembrane and soluble isoforms of heparin-binding EGF-like growth factor regulate distinct processes in the pancreas

Dual function of Langerhans cells in skin TSLP-promoted TFH differentiation in mouse atopic dermatitis

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

Suchergebnisse filtern